Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Tear gas and arrests: Iranian regime continues crackdown on protesters amid economic unrest - 2In the stomach of a mummified wolf pup, scientists find DNA from a woolly rhinoceros
- 3Living in the dark: Gaza’s struggle for electricity
- 4Inflammatory Merz remarks on migrants' violence against women slammed
- 5'No Kings' protests live updates: More than 8 million turned out across all 50 states, organizers say
- 21 Incredibly Entertaining Contemplations To Observe Consistently
- Figure out How to Track the Establishment of New 5G Pinnacles
- Paratroopers kill terrorist who threw rocks at Israeli citizens, soldiers near Ofra in West Bank
- Overhaul Your Rest: Tips for a Serene Evening
- Jupiter and the moon take a sunset stroll on March 26. Here's how to see it
- The most effective method to Oversee Unsold SUVs in the Car Business
- Beating Scholastic Difficulties: Understudy Examples of overcoming adversity
- Scientists uncover an ant assassination scheme that helps a parasitic queen rise to power
- Global measles cases drop 71% in 24 years as vaccination coverage improves, WHO says
